...
首页> 外文期刊>American journal of therapeutics >Pharmacodynamic optimization of warfarin therapy II.
【24h】

Pharmacodynamic optimization of warfarin therapy II.

机译:华法林治疗的药效优化II。

获取原文
获取原文并翻译 | 示例
           

摘要

A pharmacodynamic (E(max)) model for optimizing warfarin initiation had previously been reported. This study assessed the validity of this model, adjusted further for age in both the initial cohort and another cohort distinct from that used for the formulation of the model. Thirty-one patients undergoing oral anticoagulation for mainly cardiac indications were recruited from Kuala Lumpur. Thirty-four patients undergoing oral anticoagulation for deep vein thrombosis were recruited from Cambridge. They were studied for their anticoagulant response to the initiation of warfarin. The former were intuitively dosed after a 2-day loading of 10 mg warfarin/d. The latter all were commenced on warfarin via a standard 4-day induction protocol of Fennerty et al that allows early estimation of the required maintenance dose. The actual maintenance doses in both cohorts were compared with their predicted doses on the initiation of therapy that was calculated both from this model and from the induction protocol of Fennerty et al. The third day's international normalized ratio and age combination was additive in terms of their influence on the maintenance dose. The predictive model in both cohorts returned similar results and explained at least two thirds of the interindividual variability in warfarin maintenance dose requirements, whereas the induction protocol of Fennerty et al explained only one third of this interindividual variability. Use of this model in the form of the included nomogram should be able to decrease both the occurrence of either under- or overanticoagulation as well as the time taken to initiate treatment and decide the correct maintenance dose during the initiation of oral anticoagulation with warfarin in hospitals. A prospective evaluation of the nomogram is recommended.
机译:先前已报道了用于优化华法林起始的药效学(E(max))模型。这项研究评估了该模型的有效性,并在初始队列和另一个不同于模型制定的队列中针对年龄进行了进一步调整。从吉隆坡招募了31位主要针对心脏适应症的患者接受口服抗凝治疗。从剑桥招募了34位因深静脉血栓形成而接受口服抗凝治疗的患者。研究了它们对华法林引发的抗凝反应。前者在每天服用10毫克华法林/天2天后直观地服用。后者全部通过Fennerty等人的标准4天诱导方案开始于华法林治疗,该方案可及早估算所需的维持剂量。将两个队列中的实际维持剂量与根据该模型和Fennerty等人的诱导方案计算的开始治疗时的预测剂量进行比较。第三天的国际标准化比例和年龄组合对维持剂量有影响。两个队列中的预测模型均返回了相似的结果,并解释了华法林维持剂量要求中个体间差异的至少三分之二,而Fennerty等人的诱导方案仅解释了个体间差异的三分之一。以随附的诺模图形式使用此模型应能够减少医院中使用华法林的口服抗凝治疗期间抗凝不足或过度抗凝的发生以及开始治疗所需的时间并确定正确的维持剂量。建议对诺模图进行前瞻性评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号